Researchers at University of New Mexico Health Sciences Center Release New Data on Mucormycosis (Breaking the mold: Insights into the clinical management and outcomes of rhinocerebral mucormycosis in adults).

A recent report from the University of New Mexico Health Sciences Center discusses the clinical management and outcomes of rhinocerebral mucormycosis, a rare and life-threatening fungal infection that affects the sinuses, nasal passages, and brain. The study focused on 10 patients who received antifungal therapy within 24 hours of diagnosis. The researchers found that combination antifungal therapy did not significantly improve outcomes compared to monotherapy, and the overall mortality rate was 50%. The study concludes that further research is needed to optimize management approaches for this infection. [Extracted from the article]